Cost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan

Objectives Our study compares two national COVID-19 vaccination plan strategies—high-risk prioritization and no prioritization—and estimates their cost-effectiveness compared with no vaccination, to generate possible recommendations for future vaccination plans. Methods We developed a Markov discret...

Full description

Autores:
Morales-Zamora, Gilberto
Espinosa Eco, Oscar
Puertas, Edwin
Fernández, Juan Carlos
Hernández, José
Zakzuk, Verónica
Cepeda, Magda
Alvis-Guzmán, Nelson
Castañeda-Orjuela, Carlos
Paternina-Caicedo, Angel
Tipo de recurso:
Article of journal
Fecha de publicación:
2022
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/9372
Acceso en línea:
https://hdl.handle.net/11323/9372
https://doi.org/10.1016/j.vhri.2022.04.004
https://repositorio.cuc.edu.co/
Palabra clave:
Colombia
Cost-effectiveness
Modeling
Severe acute respiratory syndrome coronavirus 2
Vaccination
Rights
embargoedAccess
License
© 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.
id RCUC2_3c131cecdc7855bf69a327ea7f0edaa0
oai_identifier_str oai:repositorio.cuc.edu.co:11323/9372
network_acronym_str RCUC2
network_name_str REDICUC - Repositorio CUC
repository_id_str
dc.title.eng.fl_str_mv Cost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan
title Cost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan
spellingShingle Cost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan
Colombia
Cost-effectiveness
Modeling
Severe acute respiratory syndrome coronavirus 2
Vaccination
title_short Cost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan
title_full Cost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan
title_fullStr Cost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan
title_full_unstemmed Cost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan
title_sort Cost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination plan
dc.creator.fl_str_mv Morales-Zamora, Gilberto
Espinosa Eco, Oscar
Puertas, Edwin
Fernández, Juan Carlos
Hernández, José
Zakzuk, Verónica
Cepeda, Magda
Alvis-Guzmán, Nelson
Castañeda-Orjuela, Carlos
Paternina-Caicedo, Angel
dc.contributor.author.spa.fl_str_mv Morales-Zamora, Gilberto
Espinosa Eco, Oscar
Puertas, Edwin
Fernández, Juan Carlos
Hernández, José
Zakzuk, Verónica
Cepeda, Magda
Alvis-Guzmán, Nelson
Castañeda-Orjuela, Carlos
Paternina-Caicedo, Angel
dc.subject.proposal.spa.fl_str_mv Colombia
topic Colombia
Cost-effectiveness
Modeling
Severe acute respiratory syndrome coronavirus 2
Vaccination
dc.subject.proposal.eng.fl_str_mv Cost-effectiveness
Modeling
Severe acute respiratory syndrome coronavirus 2
Vaccination
description Objectives Our study compares two national COVID-19 vaccination plan strategies—high-risk prioritization and no prioritization—and estimates their cost-effectiveness compared with no vaccination, to generate possible recommendations for future vaccination plans. Methods We developed a Markov discrete-time, compartmental, deterministic model stratified by Colombian departments, healthcare workers, comorbidities, and age groups and calibrated to seroprevalence, cases, and deaths. The model simulates three scenarios: no vaccination, no prioritization of vaccination, and prioritization of high-risk population. The study presents the perspective of the health system of Colombia, including the direct health costs financed by the government and the direct health outcomes related to the infection. We measured symptomatic cases, deaths, and costs for each of the three scenarios from the start of the vaccination rollout to February 20, 2023. Results Both for the base-case and across multiple sensitivity analyses, the high-risk prioritization proves to be the most cost-effective of the considered strategies. An increment of US$255 million results in an incremental cost-effectiveness ratio of US$3339 per disability-adjusted life-year avoided. The simulations show that prioritization of high-risk population reduces symptomatic cases by 3.4% and deaths by 20.1% compared with no vaccination. The no-prioritization strategy is still cost-effective, with an incremental cost-effectiveness ratio of US$5223.66, but the sensitivity analysis the show potential risks of losing cost-effectiveness under the cost-effectiveness threshold (one gross domestic product per averted disability-adjusted life-year). Conclusions The high-risk prioritization strategy is consistently more cost-effective than the no-prioritization strategy across multiple scenarios. High-risk prioritization is the recommended strategy in low-resource settings to reduce the burden of disease.
publishDate 2022
dc.date.accessioned.none.fl_str_mv 2022-07-14T19:54:25Z
dc.date.available.none.fl_str_mv 2022-07-14T19:54:25Z
2023
dc.date.issued.none.fl_str_mv 2022
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
format http://purl.org/coar/resource_type/c_6501
dc.identifier.citation.spa.fl_str_mv Gilberto Morales-Zamora, Oscar Espinosa, Edwin Puertas, Juan Carlos Fernández, José Hernández, Verónica Zakzuk, Magda Cepeda, Nelson Alvis-Gúzman, Carlos Castañeda-Orjuela, Angel Paternina-Caicedo, Cost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia: Comparison of High-Risk Prioritization and No Prioritization Strategies With the Absence of a Vaccination Plan, Value in Health Regional Issues, Volume 31, 2022, Pages 101-110, ISSN 2212-1099, https://doi.org/10.1016/j.vhri.2022.04.004.
dc.identifier.issn.spa.fl_str_mv 2212-1099
dc.identifier.uri.spa.fl_str_mv https://hdl.handle.net/11323/9372
dc.identifier.url.spa.fl_str_mv https://doi.org/10.1016/j.vhri.2022.04.004
dc.identifier.doi.spa.fl_str_mv 10.1016/j.vhri.2022.04.004
dc.identifier.eissn.spa.fl_str_mv 2212-1102
dc.identifier.instname.spa.fl_str_mv Corporación Universidad de la Costa
dc.identifier.reponame.spa.fl_str_mv REDICUC - Repositorio CUC
dc.identifier.repourl.spa.fl_str_mv https://repositorio.cuc.edu.co/
identifier_str_mv Gilberto Morales-Zamora, Oscar Espinosa, Edwin Puertas, Juan Carlos Fernández, José Hernández, Verónica Zakzuk, Magda Cepeda, Nelson Alvis-Gúzman, Carlos Castañeda-Orjuela, Angel Paternina-Caicedo, Cost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia: Comparison of High-Risk Prioritization and No Prioritization Strategies With the Absence of a Vaccination Plan, Value in Health Regional Issues, Volume 31, 2022, Pages 101-110, ISSN 2212-1099, https://doi.org/10.1016/j.vhri.2022.04.004.
2212-1099
10.1016/j.vhri.2022.04.004
2212-1102
Corporación Universidad de la Costa
REDICUC - Repositorio CUC
url https://hdl.handle.net/11323/9372
https://doi.org/10.1016/j.vhri.2022.04.004
https://repositorio.cuc.edu.co/
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofjournal.spa.fl_str_mv Value in Health Regional Issues
dc.relation.references.spa.fl_str_mv 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534 [published correction appears in Lancet Infect Dis. 2020;20(9):e215].
2. Davies N, Kucharski A, Eggo R, Gimma A, Edmunds W. Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Health. 2020;5(7):e375–e385.
3. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of nonpharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257–261.
4. Voysey M, Clemens S, Madhi S, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of 4 randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
5. Baden L, El Sahly H, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
6. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423.
7. Polack F, Thomas S, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
8. Knoll M, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74.
9. Li Q, Guan X,Wu P, et al. Early transmission dynamics inWuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207.
10. Global economic prospects. Resumen. https://www.bancomundial.org/es/publication/global-economic-prospects. Accessed December 23, 2020.
11. Institute for Health Metrics and Evaluation. University of Washington. Healthdata – Global Burden of Disease. University of Washington; 2021. https://vizhub.healthdata.org/gbd-results/.
12. Ministerio de Salud y Protección Social. Base de Datos Única de Afiliados (BDUA). 2012-2020;Vol 2020. https://servicios.adres.gov.co/BDUA/ConsultaAfiliados-BDUA.
13. Ministerio de Salud y Protección Social. Departamento Administrativo Nacional de Estadística. Estadísticas Vitales. 2012-2019;Vol 2020. https://www.dane.gov.co/index.php/servicios-al-ciudadano/281-demograficas/estadisticas-vitales.
14. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford, United Kingdom: Oxford University Press; 2006.
15. Ministerio de Salud y Protección Social. Base de datos de la Suficiencia del Aseguramiento en Salud. Vol. 2021; 2012-2018.
16. Ministerio de Salud y Protección Social. Base de Datos del Registro Único Nacional de Talento Humano en Salud. (ReTHUS). 2020. https://web.sispro.gov.co/THS/Cliente/ConsultasPublicas/ConsultaPublicaDeTHxIdentificacion.aspx.
17. Verity R, Okell L, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–677 [published correction appears in Lancet Infect Dis. 2020;20(6):e116].
18. Instituto Nacional de Salud. Base de datos de Casos. COVID-19 en Colombia; 2020. https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx.
19. Prem K, Cook A, Jit M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput Biol. 2017;13(9): e1005697.
20. Google. COVID-19 Community Mobility Reports. https://www.google.com/covid19/mobility/.
21. Mutual Ser EPS. Mutual Ser EPS COVID-19 recorded cases. 2020.
22. Departamento Administrativo Nacional de Estadística. Producto Interno Bruto – Datos actualizados para. Vol. 2021. 2020; https://www.dane.gov.co/index.php/estadisticas-por-tema/cuentas-nacionales/cuentas-nacionalestrimestrales/pib-informacion-tecnica.
23. Departamento Administrativo Nacional de Estadística, ed. Censo Nacional de Poblacion y Vivienda 2018. Departamento Administrativo Nacional de Estadística; 2018. https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/censo-nacional-de-poblacion-y-vivenda-2018.
24. Nelder J, Mead R. A simplex method for function minimization. Comput J. 1965;7(4):308–313.
25. Huang Y, McColl W. Improved simplex method for function minimization. Proc IEEE Int Conf Syst Man Cybern. 1996;3:1702–1705.
26. Davies N, Abbott S, Barnard R, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538). eabg3055.
dc.relation.citationendpage.spa.fl_str_mv 110
dc.relation.citationstartpage.spa.fl_str_mv 101
dc.relation.citationvolume.spa.fl_str_mv 31
dc.rights.spa.fl_str_mv © 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.
Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/embargoedAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_f1cf
rights_invalid_str_mv © 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.
Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)
https://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_f1cf
eu_rights_str_mv embargoedAccess
dc.format.extent.spa.fl_str_mv 10 páginas
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.coverage.country.none.fl_str_mv Colombia
dc.publisher.spa.fl_str_mv Elsevier USA
dc.publisher.place.spa.fl_str_mv United States
institution Corporación Universidad de la Costa
dc.source.url.spa.fl_str_mv https://www.valuehealthregionalissues.com/article/S2212-1099(22)00110-8/fulltext#relatedArticles
bitstream.url.fl_str_mv https://repositorio.cuc.edu.co/bitstreams/ee03a872-df72-4f06-b18c-fdb02a054941/download
https://repositorio.cuc.edu.co/bitstreams/4f9767b4-a8e1-4842-bc87-bf423f431d88/download
https://repositorio.cuc.edu.co/bitstreams/9e99e340-d537-413f-9b34-7396cacc81dd/download
https://repositorio.cuc.edu.co/bitstreams/1bb19640-40d4-4ab8-8433-6bc8b97cc7da/download
bitstream.checksum.fl_str_mv a052d7960637160b7f14677d5e6f1294
e30e9215131d99561d40d6b0abbe9bad
35e245328de3b8507de3e9b74d18cdb3
f8bfe39288891873d80821282c6a23e4
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio de la Universidad de la Costa CUC
repository.mail.fl_str_mv repdigital@cuc.edu.co
_version_ 1811760688237903872
spelling Morales-Zamora, GilbertoEspinosa Eco, OscarPuertas, EdwinFernández, Juan CarlosHernández, JoséZakzuk, VerónicaCepeda, MagdaAlvis-Guzmán, NelsonCastañeda-Orjuela, CarlosPaternina-Caicedo, Angel2022-07-14T19:54:25Z20232022-07-14T19:54:25Z2022Gilberto Morales-Zamora, Oscar Espinosa, Edwin Puertas, Juan Carlos Fernández, José Hernández, Verónica Zakzuk, Magda Cepeda, Nelson Alvis-Gúzman, Carlos Castañeda-Orjuela, Angel Paternina-Caicedo, Cost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia: Comparison of High-Risk Prioritization and No Prioritization Strategies With the Absence of a Vaccination Plan, Value in Health Regional Issues, Volume 31, 2022, Pages 101-110, ISSN 2212-1099, https://doi.org/10.1016/j.vhri.2022.04.004.2212-1099https://hdl.handle.net/11323/9372https://doi.org/10.1016/j.vhri.2022.04.00410.1016/j.vhri.2022.04.0042212-1102Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Objectives Our study compares two national COVID-19 vaccination plan strategies—high-risk prioritization and no prioritization—and estimates their cost-effectiveness compared with no vaccination, to generate possible recommendations for future vaccination plans. Methods We developed a Markov discrete-time, compartmental, deterministic model stratified by Colombian departments, healthcare workers, comorbidities, and age groups and calibrated to seroprevalence, cases, and deaths. The model simulates three scenarios: no vaccination, no prioritization of vaccination, and prioritization of high-risk population. The study presents the perspective of the health system of Colombia, including the direct health costs financed by the government and the direct health outcomes related to the infection. We measured symptomatic cases, deaths, and costs for each of the three scenarios from the start of the vaccination rollout to February 20, 2023. Results Both for the base-case and across multiple sensitivity analyses, the high-risk prioritization proves to be the most cost-effective of the considered strategies. An increment of US$255 million results in an incremental cost-effectiveness ratio of US$3339 per disability-adjusted life-year avoided. The simulations show that prioritization of high-risk population reduces symptomatic cases by 3.4% and deaths by 20.1% compared with no vaccination. The no-prioritization strategy is still cost-effective, with an incremental cost-effectiveness ratio of US$5223.66, but the sensitivity analysis the show potential risks of losing cost-effectiveness under the cost-effectiveness threshold (one gross domestic product per averted disability-adjusted life-year). Conclusions The high-risk prioritization strategy is consistently more cost-effective than the no-prioritization strategy across multiple scenarios. High-risk prioritization is the recommended strategy in low-resource settings to reduce the burden of disease.10 páginasapplication/pdfengElsevier USAUnited States© 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/embargoedAccesshttp://purl.org/coar/access_right/c_f1cfCost-effectiveness analysis of strategies of Covid-19 vaccination in Colombia: comparison of high-risk prioritization and no prioritization strategies with the absence of a vaccination planArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85https://www.valuehealthregionalissues.com/article/S2212-1099(22)00110-8/fulltext#relatedArticlesColombiaValue in Health Regional Issues1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534 [published correction appears in Lancet Infect Dis. 2020;20(9):e215].2. Davies N, Kucharski A, Eggo R, Gimma A, Edmunds W. Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Health. 2020;5(7):e375–e385.3. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of nonpharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257–261.4. Voysey M, Clemens S, Madhi S, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of 4 randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.5. Baden L, El Sahly H, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.6. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423.7. Polack F, Thomas S, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.8. Knoll M, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74.9. Li Q, Guan X,Wu P, et al. Early transmission dynamics inWuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207.10. Global economic prospects. Resumen. https://www.bancomundial.org/es/publication/global-economic-prospects. Accessed December 23, 2020.11. Institute for Health Metrics and Evaluation. University of Washington. Healthdata – Global Burden of Disease. University of Washington; 2021. https://vizhub.healthdata.org/gbd-results/.12. Ministerio de Salud y Protección Social. Base de Datos Única de Afiliados (BDUA). 2012-2020;Vol 2020. https://servicios.adres.gov.co/BDUA/ConsultaAfiliados-BDUA.13. Ministerio de Salud y Protección Social. Departamento Administrativo Nacional de Estadística. Estadísticas Vitales. 2012-2019;Vol 2020. https://www.dane.gov.co/index.php/servicios-al-ciudadano/281-demograficas/estadisticas-vitales.14. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford, United Kingdom: Oxford University Press; 2006.15. Ministerio de Salud y Protección Social. Base de datos de la Suficiencia del Aseguramiento en Salud. Vol. 2021; 2012-2018.16. Ministerio de Salud y Protección Social. Base de Datos del Registro Único Nacional de Talento Humano en Salud. (ReTHUS). 2020. https://web.sispro.gov.co/THS/Cliente/ConsultasPublicas/ConsultaPublicaDeTHxIdentificacion.aspx.17. Verity R, Okell L, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–677 [published correction appears in Lancet Infect Dis. 2020;20(6):e116].18. Instituto Nacional de Salud. Base de datos de Casos. COVID-19 en Colombia; 2020. https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx.19. Prem K, Cook A, Jit M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput Biol. 2017;13(9): e1005697.20. Google. COVID-19 Community Mobility Reports. https://www.google.com/covid19/mobility/.21. Mutual Ser EPS. Mutual Ser EPS COVID-19 recorded cases. 2020.22. Departamento Administrativo Nacional de Estadística. Producto Interno Bruto – Datos actualizados para. Vol. 2021. 2020; https://www.dane.gov.co/index.php/estadisticas-por-tema/cuentas-nacionales/cuentas-nacionalestrimestrales/pib-informacion-tecnica.23. Departamento Administrativo Nacional de Estadística, ed. Censo Nacional de Poblacion y Vivienda 2018. Departamento Administrativo Nacional de Estadística; 2018. https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/censo-nacional-de-poblacion-y-vivenda-2018.24. Nelder J, Mead R. A simplex method for function minimization. Comput J. 1965;7(4):308–313.25. Huang Y, McColl W. Improved simplex method for function minimization. Proc IEEE Int Conf Syst Man Cybern. 1996;3:1702–1705.26. Davies N, Abbott S, Barnard R, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538). eabg3055.11010131ColombiaCost-effectivenessModelingSevere acute respiratory syndrome coronavirus 2VaccinationPublicationORIGINALCost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia.pdfCost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia.pdfapplication/pdf1777340https://repositorio.cuc.edu.co/bitstreams/ee03a872-df72-4f06-b18c-fdb02a054941/downloada052d7960637160b7f14677d5e6f1294MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-83196https://repositorio.cuc.edu.co/bitstreams/4f9767b4-a8e1-4842-bc87-bf423f431d88/downloade30e9215131d99561d40d6b0abbe9badMD52TEXTCost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia.pdf.txtCost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia.pdf.txttext/plain43003https://repositorio.cuc.edu.co/bitstreams/9e99e340-d537-413f-9b34-7396cacc81dd/download35e245328de3b8507de3e9b74d18cdb3MD53THUMBNAILCost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia.pdf.jpgCost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia.pdf.jpgimage/jpeg15353https://repositorio.cuc.edu.co/bitstreams/1bb19640-40d4-4ab8-8433-6bc8b97cc7da/downloadf8bfe39288891873d80821282c6a23e4MD5411323/9372oai:repositorio.cuc.edu.co:11323/93722024-09-16 16:50:17.417https://creativecommons.org/licenses/by-nc-nd/4.0/© 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.open.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.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